Am J Transplant, Volume 19, Suppl 3 Archives - Page 19 of 214 - ATC Abstracts

2019 American Transplant Congress
NK Cells Are Associated with Alloimmune Failure in Transplanted Children
E. T. Chambers¹, O. Martinez², M. Robien³, C. Chan¹, R. Ettenger⁴, P. Grimm⁵, H. Lee¹, E. Reed⁴, L. Stempora⁶, M. Sarwal⁷, B. Warshaw⁸, C. Zhao¹, A. D. Kirk⁶
¹Pediatrics, Duke University, Durham, NC, ²Surgery, Stanford, Palo Alto, CA, ³NIH, Bethesda, MD, ⁴Pediatrics, UCLA, Los Angeles, CA, ⁵Pediatrics, Stanford, Stanford, CA, ⁶Surgery, Duke University, Durham, NC, ⁷Pediatrics, UCSF, San Francisco, CA, ⁸Pediatrics, Emory University, Atlanta, GA
*Purpose: Alloimmune failure, defined as the development of donor specific antibody (DSA) and/ or allograft rejection, remains a significant complication in pediatric kidney transplantation. NK…
2019 American Transplant Congress
Apoptotic Exosome-Like Vesicles Induce Endothelial Cell Plasticity and Accelerate Allograft Vascular Remodeling
F. Migneault¹, M. Dieudé¹, J. Turgeon¹, A. Karakeussian Rimbaud¹, D. Beillevaire¹, M. Hardy², A. Brodeur¹, N. Thibodeau¹, C. Perreault², M. Hébert¹
¹CRCHUM, Montreal, QC, Canada, ²IRIC, Montreal, QC, Canada
*Purpose: Acute vascular rejection of allografts is associated with endothelial apoptosis which in turn contributes to the development of transplant vasculopathy. We previously showed that…
2019 American Transplant Congress
Preliminary Mechanistic Studies of Regulatory Dendritic Cell (DCreg) Cell Infusion in Living Donor Liver Transplant Recipients
A. Thomson, C. Macedo, A. Zahorchak, H. Dai, A. Humar, F. G. Lakkis, M. Styn, D. Metes
Starzl Transplantation Institute, Pittsburgh, PA
*Purpose: This is a first-in-human phase I/II safety and preliminary efficacy trial of donor-derived regulatory dendritic cells (DCreg) in living donor liver transplantation (LTx) in…
2019 American Transplant Congress
Efficacy and Safety Outcomes with De Novo Use of Everolimus-Based Regimen in Renal Transplant Recipients with Delayed Graft Function from the TRANSFORM Study
S. Chadban¹, F. Oppenheimer¹, F. Citterio¹, O. Witzke¹, V. D. Garcia¹, A. Gutierrez-Dalmau¹, P. Narvekar², M. P. Hernandez Gutierrez², P. Bernhardt², A. Wiseman¹
¹TRANSFORM Study Group, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
*Purpose: To evaluate the effect of everolimus with reduced CNI (EVR+rCNI) vs mycophenolic acid with standard CNI (MPA+sCNI) on efficacy and safety outcomes in RTxR…
2019 American Transplant Congress
Long-Term Outcomes in Patients with Obesity and Renal Disease after Sleeve Gastrectomy
A. Kassam, A. Mirza, Y. Kim, E. S. Woodle, S. A. Shah, M. C. Cuffy, R. C. Quillin III, L. Sage Silski, A. Govil, M. Cardi, T. S. Diwan
Department of Surgery, University of Cincinnati, Cincinnati, OH
*Purpose: Morbid obesity is a barrier to kidney transplantation in patients with end-stage renal disease (ESRD) and is associated with progression of chronic kidney disease…
2019 American Transplant Congress
Effect of Everolimus with Reduced-Exposure Tacrolimus and Early Steroid Elimination in Pediatric Kidney Transplant Recipients: 36-Month Outcomes from the CRADLE Study
H. Tedesco Silva¹, R. Ettenger¹, A. Bjerre¹, M. Christian¹, L. Dello Strologo¹, S. D. Marks¹, L. Pape¹, P. Lopez², M. Cousin², P. Pandey², B. Rauer², M. Meier², B. Tönshoff¹
¹A2314 Study Group, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
*Purpose: To compare 36-month (M) efficacy and safety outcomes of an everolimus+reduced-exposure tacrolimus (EVR+rTAC)+steroids (CS) withdrawal regimen vs mycophenolate mofetil+standard-exposure TAC (MMF+sTAC)+CS in pediatric kidney…
2019 American Transplant Congress
Targeting Cell Metabolism for Efficient Large-Scale Expansion of Functional Regulatory T Cells
R. Gedaly-Eidelman, F. Marti, L. Turcios, E. Chacon, D. Valvi
University of Kentucky, Lexington, KY
*Purpose: A growing body of evidence recognizes the balance between graft-reactive effector T cells and graft-protective regulatory T cells (Tregs) as the ultimate determinant of…
2019 American Transplant Congress
Decay Accelerating Factor (DAF) Regulates Germinal Center B-cell and Alloantibody Formation
A. Cumpelik¹, G. Varano², D. Heja¹, D. Homann³, S. Lira⁴, D. Dominguez-Sola², P. S. Heeger¹
¹Nephrology, Mount Sinai School of Medicine, New York, NY, ²Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, ³Medicine, Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, NY, ⁴Clinical Immunology, Mount Sinai School of Medicine, New York, NY
*Purpose: High affinity IgG antibodies including alloantibodies result from germinal center (GC) reactions in which somatic hypermutation and positive selection cause affinity maturation. When we…
2019 American Transplant Congress
Belatacept Treated Patients Experience Improved Health-Related Quality of Life and Lower Symptom Distress Compared to Cyclosporine Treated Patients: An Analysis of the Benefit and Benefit-EXT Cohorts
M. J. Everly¹, I. Purnajo¹, J. L. Beaumont¹, M. Polinsky², E. Alemao²
¹Terasaki Research Institute, Los Angeles, CA, ²Bristol Myers Squibb, Princeton, NJ
*Purpose: New immunosuppressive agents in transplant should not only be efficacious but also help patients feel better (i.e. lower patient reported symptoms and improve health…
2019 American Transplant Congress
Belatacept Based CNI Free Immunosuppression in Pancreas Transplantation. Results at 4 Years
J. Chen, J. Fridell, M. Yaqub, T. Taber, D. MIshler, O. Adebiyi, M. Mujtaba, A. Sharfuddin
Indiana University School of Medicine, Indianapolis, IN
*Purpose: CNI based Immunosuppression is a well known risk factor for worsening renal function. We report our experience in converting Pancreas Transplant recipients from tacrolimus…